Gilead coronavirus treatment trial shows rapid recovery: Report
Gilead Sciences’ potential coronavirus treatment is reportedly showing signs of optimism in trial. FOX Business’ Jackie DeAngelis with more.
A coronavirus test by biopharmaceutical company Gilead failed a clinical trial in China, the Financial Times reported.
Continue Reading Below
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC. | 76.57 | -4.74 | -5.83% |
The antiviral drug remdesivir did not help speed the recovery of COVID-19 patients, according to FT and Stat News, which both cite a summary of the report that was initially shared by the World Health Organization before it was taken down.
In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. (Gilead Sciences via AP) "A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments," WHO spokesperson Tarik Jasarevic told Stat. A spokesperson for Gilead said the WHO document contained "inappropriate characterization of the study. GET FOX BUSINESS ON THE GO BY CLICKING HERE Source: Read Full Article